Sense and nonsense in sensors

Open Access
Authors
  • J. Hermanides
  • J.H. DeVries
Publication date 2010
Journal Diabetologia
Volume | Issue number 53 | 4
Pages (from-to) 593-596
Organisations
  • Faculty of Medicine (AMC-UvA)
Abstract Continuous subcutaneous glucose monitoring (CGM) is a developing technology in the treatment of diabetes mellitus. The first randomised controlled trials on its efficacy have been performed. In several studies, CGM lowered HbA1c in adult patients with suboptimally controlled type 1 diabetes mellitus, when selecting compliant patients who tolerate the device. However, as a preventive tool for hypoglycaemia, CGM has not fulfilled the great expectations. Increasing reimbursement of CGM is expected in the near future, awaiting studies on cost-effectiveness
Document type Article
Published at
https://doi.org/10.1007/s00125-009-1649-4 (Final published version)
Downloads
340160.pdf (Final published version)
Permalink to this page
Back